CY1123344T1 - Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων - Google Patents
Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακωνInfo
- Publication number
- CY1123344T1 CY1123344T1 CY20201100867T CY201100867T CY1123344T1 CY 1123344 T1 CY1123344 T1 CY 1123344T1 CY 20201100867 T CY20201100867 T CY 20201100867T CY 201100867 T CY201100867 T CY 201100867T CY 1123344 T1 CY1123344 T1 CY 1123344T1
- Authority
- CY
- Cyprus
- Prior art keywords
- corticosteroid
- conditions
- othlic
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904887P | 2013-11-15 | 2013-11-15 | |
| PCT/US2014/065804 WO2015073895A1 (en) | 2013-11-15 | 2014-11-14 | Methods of treatment of ocular conditions with a sustained drug delivery implant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123344T1 true CY1123344T1 (el) | 2021-12-31 |
Family
ID=52001114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100867T CY1123344T1 (el) | 2013-11-15 | 2020-09-14 | Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20150140062A1 (https=) |
| EP (2) | EP3714875A1 (https=) |
| JP (2) | JP6675307B2 (https=) |
| KR (3) | KR20240058976A (https=) |
| CN (1) | CN105764517A (https=) |
| AU (4) | AU2014348369B2 (https=) |
| CA (1) | CA2929689A1 (https=) |
| CL (1) | CL2016001167A1 (https=) |
| CY (1) | CY1123344T1 (https=) |
| DK (1) | DK3068403T3 (https=) |
| ES (1) | ES2819215T5 (https=) |
| HU (1) | HUE050913T2 (https=) |
| IL (2) | IL245548A0 (https=) |
| MX (2) | MX2016006334A (https=) |
| MY (1) | MY176039A (https=) |
| NZ (1) | NZ719953A (https=) |
| PH (1) | PH12016500869A1 (https=) |
| PL (1) | PL3068403T3 (https=) |
| PT (1) | PT3068403T (https=) |
| RU (1) | RU2690841C1 (https=) |
| SG (1) | SG10201809363SA (https=) |
| SI (1) | SI3068403T1 (https=) |
| UA (1) | UA122117C2 (https=) |
| WO (1) | WO2015073895A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3324944A4 (en) * | 2015-07-23 | 2019-04-03 | Aerie Pharmaceuticals, Inc. | INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE |
| JP2019534063A (ja) | 2016-09-02 | 2019-11-28 | エンビシャ セラピューティクス インコーポレイテッド | インプラントアプリケータ |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| CA3174217A1 (en) * | 2020-07-16 | 2022-01-20 | Ocular Therapeutix, Inc. | Ocular insert containing a glucocorticoid |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| AU2002236495B2 (en) | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| CN103402582A (zh) * | 2011-02-11 | 2013-11-20 | 普西维达公司 | 使用抗水肿疗法治疗黄斑水肿的方法 |
-
2014
- 2014-11-14 CA CA2929689A patent/CA2929689A1/en active Pending
- 2014-11-14 RU RU2016119132A patent/RU2690841C1/ru active
- 2014-11-14 PT PT148057680T patent/PT3068403T/pt unknown
- 2014-11-14 PL PL14805768T patent/PL3068403T3/pl unknown
- 2014-11-14 SI SI201431652T patent/SI3068403T1/sl unknown
- 2014-11-14 WO PCT/US2014/065804 patent/WO2015073895A1/en not_active Ceased
- 2014-11-14 EP EP20173457.1A patent/EP3714875A1/en active Pending
- 2014-11-14 NZ NZ719953A patent/NZ719953A/en not_active IP Right Cessation
- 2014-11-14 KR KR1020247013455A patent/KR20240058976A/ko not_active Ceased
- 2014-11-14 CN CN201480062403.7A patent/CN105764517A/zh active Pending
- 2014-11-14 EP EP14805768.0A patent/EP3068403B2/en active Active
- 2014-11-14 KR KR1020227018854A patent/KR20220082934A/ko not_active Ceased
- 2014-11-14 MX MX2016006334A patent/MX2016006334A/es unknown
- 2014-11-14 US US14/542,189 patent/US20150140062A1/en not_active Abandoned
- 2014-11-14 JP JP2016530991A patent/JP6675307B2/ja active Active
- 2014-11-14 KR KR1020167015466A patent/KR102475746B1/ko active Active
- 2014-11-14 HU HUE14805768A patent/HUE050913T2/hu unknown
- 2014-11-14 AU AU2014348369A patent/AU2014348369B2/en active Active
- 2014-11-14 UA UAA201605224A patent/UA122117C2/uk unknown
- 2014-11-14 ES ES14805768T patent/ES2819215T5/es active Active
- 2014-11-14 SG SG10201809363SA patent/SG10201809363SA/en unknown
- 2014-11-14 DK DK14805768.0T patent/DK3068403T3/da active
- 2014-11-14 MY MYPI2016000899A patent/MY176039A/en unknown
-
2016
- 2016-05-09 IL IL245548A patent/IL245548A0/en unknown
- 2016-05-11 PH PH12016500869A patent/PH12016500869A1/en unknown
- 2016-05-13 MX MX2022002306A patent/MX2022002306A/es unknown
- 2016-05-13 CL CL2016001167A patent/CL2016001167A1/es unknown
-
2019
- 2019-12-13 JP JP2019225503A patent/JP7022735B2/ja active Active
-
2020
- 2020-06-30 AU AU2020204362A patent/AU2020204362A1/en not_active Abandoned
- 2020-09-14 CY CY20201100867T patent/CY1123344T1/el unknown
-
2022
- 2022-02-23 IL IL290837A patent/IL290837A/en unknown
- 2022-06-29 AU AU2022204607A patent/AU2022204607A1/en not_active Abandoned
-
2024
- 2024-08-09 AU AU2024205640A patent/AU2024205640B2/en active Active
-
2025
- 2025-02-21 US US19/060,301 patent/US20250319031A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123344T1 (el) | Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων | |
| CY1121064T1 (el) | Μειωση ενδοφθαλμιας πιεσης με ενδοθαλαμικα εμφυτευματα βιματοπροστης | |
| EP3442577A4 (en) | TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST TRANSLATION MODIFIED ANTI-VEGF FAB | |
| MX2018014763A (es) | Suministro intraocular de farmacos. | |
| CY1121511T1 (el) | Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων | |
| MX2020001340A (es) | Modelos celulares y terapias para enfermedades oculares. | |
| AR091237A1 (es) | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) | |
| CY1120393T1 (el) | Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων | |
| BR112017024531A2 (pt) | lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir) | |
| HK1218850A1 (zh) | 持续药物递送植入物 | |
| TW201613588A (en) | Ophthalmic composition | |
| ECSP12011692A (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
| HK1205461A1 (zh) | 用於眼部传输治疗剂的组合物和方法 | |
| BR112015006929A2 (pt) | sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas | |
| CY1120642T1 (el) | Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση | |
| PH12015502469A1 (en) | Fcrn-binding abolished anti-igf-ir antibodies and their use in the treatment of vascular eye diseases | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
| CY1121000T1 (el) | Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων | |
| MX2018008640A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. | |
| CY1119067T1 (el) | Διασταυρουμενο υαλουρονικο οξυ, διαδικασια για την παρασκευη του και χρηση αυτου στο αισθητικο πεδιο | |
| MX379359B (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| UY33153A (es) | Formulación tópica oftálmica de péptidos | |
| MX2020012012A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. |